An index of frontier and emerging AI labs.
Bio / AI drug discovery
Launched with $1B to build an end-to-end AI drug discovery platform combining foundation models with wet-lab data generation. Co-founded by Nobel laureate David Baker and former Stanford president Marc Tessier-Lavigne.
| Name | Xaira Therapeutics |
|---|---|
| Space | Bio / AI drug discovery |
| Founded | 2024 |
| Latest valuation | ~$4B |
| Stage | — |
| Status | active |
| HQ | San Francisco |
| Founders | Marc Tessier-Lavigne, David Baker, Hetu Kamisetty |
| Website | https://www.xaira.com |
| Careers | https://www.xaira.com/work-with-us |
| — | |
| X / Twitter | — |
| Date | Round | Amount ($M) | Valuation | Confidence |
|---|---|---|---|---|
| — | — | — | ~$1B | reported |
No founders recorded yet. Submit info.
| Date | Type | Title | Source |
|---|---|---|---|
| 2026-06-03 | added | Xaira Therapeutics added to tracker Latest valuation: ~$1B. | — |
No sources cited.
| Lab | Valuation | Founded |
|---|---|---|
| Enveda | — | 2019 |
| Helical | — | 2024 |
| Insilico Medicine | — | 2014 |
| Reliant AI | — | 2023 |
| Isomorphic Labs | >$15B | 2021 |
| insitro | ~$2.5B | 2018 |
| Generate Biomedicines | ~$2B | 2018 |
| Recursion | ~$1.75B (mkt cap) | 2013 |